NCT04917835 is a NA clinical trial of PLADUO(PX1000) in Oily Skin, sponsored by Gangnam Severance Hospital.

Who is sponsoring NCT04917835?

NCT04917835 is sponsored by Gangnam Severance Hospital.

What drugs are being tested in NCT04917835?

Interventions in NCT04917835: PLADUO(PX1000).

Is NCT04917835 still recruiting?

NCT04917835 is currently completed. Last updated 8 June 2021.

Last reviewed 2021-06-08 · How we verify

NCT04917835

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Non-thermal Plasma for Sebum Reduction in Oily Facial Skin

Completed NA Last updated 8 June 2021

What this trial tests

NA trial testing PLADUO(PX1000) in Oily Skin in 14 participants. Completed in 6 May 2020.

Timeline

15 November 2019

Primary endpoint
9 April 2020

6 May 2020

Quick facts

Lead sponsor	Gangnam Severance Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	14
Start date	15 November 2019
Primary completion	9 April 2020
Estimated completion	6 May 2020
Sites	1 location across South Korea

Drugs / interventions tested

PLADUO(PX1000)

Conditions studied

Oily Skin — all drugs for Oily Skin →

Sponsor

Gangnam Severance Hospital

Who can join

Adults 19 to 40, any sex, with Oily Skin. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to evaluate the efficacy and safety of argon-and nitrogen- non-thermal, atmospheric-pressure plasma (NTAPP) for reduction of sebum excretion in healthy volunteers with oily facial skin.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Gangnam Severance Hospital trials

Trials by the same sponsor.

NCT07505628 — AI-based Rehabilitation for Hip and Knee Surgery Patients · NA · not yet recruiting
NCT07311122 — Endocrine Therapy Base on 21-gene RS · not yet recruiting
NCT07011823 — Immune-checkpoint Blockade After Partial Breast Irradiation by Pembrolizumab in Early TNBC · Phase 2 · not yet recruiting
NCT07211451 — Axillary Nodal Burden in HER2+ and TNBC · completed
NCT06839716 — Comparison of Ropivacaine-Poloxamer 407 Hydrogel and TAP Block for Postoperative Pain Management in Laparoscopic/Robotic · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04917835 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Gangnam Severance Hospital
Last refreshed: 8 June 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04917835.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing